Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Paris, France – 1 May 2017: The risk of heart transplant rejection can be reduced by desensitising patient antibodies, according to research presented today at Heart Failure 2017 and the 4th World Congress on Acute Heart Failure.1 The breakthrough comes on the 50th anniversary of heart transplantation.
Before heart transplantation the serum of heart transplant candidates is tested for levels of anti-human leukocyte antigen (HLA) which could bind to donor HLA antigens and cause rejection of the organ. At the time of transplantation, a virtual crossmatch is conducted to determine if the patient’s anti-HLA antibodies are directed against the donor’s specific HLA antigen – if yes, they are called “donor specific anti-HLA antibody” (DSA).
“Most centres do not perform heart transplantation in patients with a high DSA level since the risk of antibody-mediated rejection is high, particularly hyper-acute rejection,” said lead author Dr Guillaume Coutance, a cardiologist at Pitié-Salpêtrière Hospital in Paris, France. “Patients then have to wait for a donor with different HLA antigens.”
To reduce the chance of rejection in these patients at high immunological risk, in 2009 Pitié-Salpêtrière Hospital began a desensitisation programme. The current study analysed the impact of the programme on survival after heart transplantations performed during 2009 to 2015.
The type of desensitisation patients receive depends on their DSA level, which is measured by mean fluorescence intensity (MFI). An MFI between 500 and 1000 is considered “low DSA” and an MFI above 1000 is considered “high DSA”. All patients receive anti-thymocyte globulins and conventional immunosuppressive therapy (calcineurin inhibitors, mycophenolate mofetil, and corticosteroids).
On top of this, patients with low DSA levels receive intravenous immunoglobulins. Patients with high DSA levels are treated with plasmapheresis before and after transplantation, followed by intravenous immunoglobulins after the complete cycle of plasmapheresis.
The study included 523 patients who were 50 years old on average and 77% were men. Nearly half (46%) of patients had no DSA, 17% had low DSA, and 37% had high DSA levels. Patients were followed-up for an average of 3.7 years and survival was compared between the three groups.
Compared to patients with no or low DSA, those with high DSA were more often younger, female, and had a ventricular assist device. The length of survival after transplantation was similar between the three groups, even after adjustment for age, sex, and having a ventricular assist device before transplantation. Survival at one year and at the end of follow-up was 79% and 73% for those with no DSA, 80% and 72% in patients with low DSA, and 84% and 76% in patients with high DSA levels, respectively (p=0.85).
Antibody-mediated rejections were more common in patients with high DSA levels (27% versus 6% in patients with no DSA). These rejections occurred early (a median of 28 days after transplantation) in patients with high DSA levels but they had no impact on survival and could be treated. Patients with high DSA levels had more bleeding complications due to perioperative plasmapheresis.
Dr Coutance said: “By desensitising patient’s antibodies, those with high immunological risk experience similar survival to patients without DSA. Pre- and post-operative plasmapheresis results in a dramatic drop in DSA levels, which reduces the risk of hyper-acute rejections and early antibody-mediated rejections. Intravenous immunoglobulins will neutralise DSA for weeks.”
“Despite this regimen, antibody-mediated rejections were frequent but they were not associated with poor outcomes,” added Dr Coutance. “Two factors might explain these good results: early diagnosis of rejection with repetitive routine biopsies, and aggressive treatment of rejections with plasmapheresis and intravenous immunoglobulins even in subclinical rejections. The increased bleeding risk is explained by the loss of coagulation factors during plasmapheresis which is important but does not seem to impact survival.”
He concluded: “This desensitisation programme could shorten waiting times and increase access to transplantation for patients at high immunological risk. However, it will probably not increase the number of transplantations since donor shortage is the limiting factor.”
ESC Press OfficeTel: +33 (0) 4 89 87 34 83Email: email@example.com
SOURCES OF FUNDING: None. DISCLOSURES: None.References and notes1Dr Coutance will present the abstract ‘Heart transplantation in patients with high immunological risk is safe when performed with a specific desensitization program’ during the session Rapid Fire 6 – Advanced heart failure which takes place on 1 May from 16:30 to 18:00 in the Agora 2.About Heart Failure 2017 and the 4th World Congress on Acute Heart FailureHeart Failure is the annual congress of the Heart Failure Association of the ESC. The 4th World Congress on Acute Heart Failure is part of the main programme of Heart Failure 2017.About the Heart Failure AssociationThe Heart Failure Association (HFA) is a registered branch of the ESC. Its aim is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.About the European Society of CardiologyThe European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.Information for journalists attending Heart Failure 2017Heart Failure 2017 takes place 29 April to 2 May in Paris, France at the Palais des Congrès. The full scientific programme is available hereFree registration applies to press representatives. Get accredited and register: here
Our Mission: To Reduce the Burden of Cardiovascular Disease
© 2019 European Society of Cardiology. All rights reserved